New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
The future of the weight loss market might not revolve around GLP-1 drugs.
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...
Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).
A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ...
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...
The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback